The content on this site is intended for healthcare professionals only

Breast

Prostate & urology

Lung & pleura

Colorectal & gastro

Melanoma & skin

Head & neck

Ovary & gynaecology

+ -

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

SABCS 2015

8 - 12 Dec 2015

TBC, San Antonio, United States of America

Biomarker driven clinical trials

Dr Oleg Gluz - West German Study Group Monchengladbach, Germany

Biomarker driven clinical trials ( Dr Oleg Gluz - West German Study Group Monchengladbach, Germany )

Buparlisib helps overcome endocrine resistance in metastatic breast cancer: BELL...

Dr Mario Campone - René Gauducheau Centre de Recherche en Cancérologie, Nantes, ...

Buparlisib helps overcome endocrine resistance in metastatic breast cancer: BELLE-2 trial results ( Dr Mario Campone - René Gauducheau Centre de Recherche en Cancérologie, Nantes, France. )

Survival outcomes from the CALGB 40603 study in triple-negative breast cancer

Dr William Sikov - Women & Infants Hospital of Rhode Island, Providence, USA

Survival outcomes from the CALGB 40603 study in triple-negative breast cancer ( Dr William Sikov - Women & Infants Hospital of Rhode Island, Providence, USA )

TH3RESA: T-DM1 improves overall survival in previously treated advanced cancer p...

Prof Hans Wildiers - University Hospital of Leuven, Leuven, Belgium

TH3RESA: T-DM1 improves overall survival in previously treated advanced cancer patients ( Prof Hans Wildiers - University Hospital of Leuven, Leuven, Belgium )

Molecular evolution of breast cancer during neoadjuvant chemotherapy

Prof Anne-Lise Børresen-Dale - Oslo University Hospital, Oslo, Norway

Molecular evolution of breast cancer during neoadjuvant chemotherapy ( Prof Anne-Lise Børresen-Dale - Oslo University Hospital, Oslo, Norway )

NSABP FB-7: Neoadjuvant therapy with neratinib plus trastuzumab in locally advan...

Dr Samuel Jacobs - NSABP Foundation, Pittsburgh, USA

NSABP FB-7: Neoadjuvant therapy with neratinib plus trastuzumab in locally advanced HER2-positive breast cancer ( Dr Samuel Jacobs - NSABP Foundation, Pittsburgh, USA )

HER2 status as predictive marker for aromatase inhibitor versus tamoxifen use in...

Dr John Bartlett - Ontario Institute for Cancer Research, Toronto, Canada

HER2 status as predictive marker for aromatase inhibitor versus tamoxifen use in early breast cancer ( Dr John Bartlett - Ontario Institute for Cancer Research, Toronto, Canada )

Trastuzumab emtansine improves overall survival versus treatment of physician's ...

Prof Hans Wildiers - University Hospital of Leuven, Leuven, Belgium

Trastuzumab emtansine improves overall survival versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cance ( Prof Hans Wildiers - University Hospital of Leuven, Leuven, Belgium )

Homologous recombination deficiency predicts neo-adjuvant chemotherapy response ...

Dr Virginia Kaklamani - UT Health Science Center, San Antonio, TX

Homologous recombination deficiency predicts neo-adjuvant chemotherapy response in triple-negative breast cancer ( Dr Virginia Kaklamani - UT Health Science Center, San Antonio, TX )

TAILORx: Genomic test helps identify low-risk women who do not need chemotherapy

Dr Virginia Kaklamani - UT Health Science Center, San Antonio, TX

TAILORx: Genomic test helps identify low-risk women who do not need chemotherapy ( Dr Virginia Kaklamani - UT Health Science Center, San Antonio, TX )

Efficacy and gene expression results from eribulin SOLTI1007 neoadjuvant study

Dr Javier Cortes - Vall d´Hebron Institute of Oncology, Barcelona, Spain

Efficacy and gene expression results from eribulin SOLTI1007 neoadjuvant study ( Dr Javier Cortes - Vall d´Hebron Institute of Oncology, Barcelona, Spain )

ER and FGFR1 interaction critical in endocrine resistant breast cancer

Dr Luigi Formisano - Vanderbilt University Nashville, USA

ER and FGFR1 interaction critical in endocrine resistant breast cancer ( Dr Luigi Formisano - Vanderbilt University Nashville, USA )

Interrupting breast cancer treatment for young women who desire pregnancy

Dr Olivia Pagani and Dr Ann Partridge

Interrupting breast cancer treatment for young women who desire pregnancy ( Dr Olivia Pagani and Dr Ann Partridge )

Treatment outcomes in patients with invasive breast cancer treated with neoadjuv...

Prof Jennifer De Los Santos - University of Alabama, Birmingham, USA

Treatment outcomes in patients with invasive breast cancer treated with neoadjuvant systemic therapy and breast MR imaging ( Prof Jennifer De Los Santos - University of Alabama, Birmingham, USA )

Novel estrogen receptor-targeting agent represents ‘quantum leap’

Dr Ganesh Raj - UT Southwestern Medical Center, Dallas, USA

Novel estrogen receptor-targeting agent represents ‘quantum leap’ ( Dr Ganesh Raj - UT Southwestern Medical Center, Dallas, USA )

Ductal carcinoma in situ: Anastrozole versus tamoxifen

Dr Terry Mamounas - UF Health Cancer Center, Orlando, USA

Ductal carcinoma in situ: Anastrozole versus tamoxifen ( Dr Terry Mamounas - UF Health Cancer Center, Orlando, USA )

Update on management of the axilla

Dr Terry Mamounas - UF Health Cancer Center, Orlando, USA

Update on management of the axilla ( Dr Terry Mamounas - UF Health Cancer Center, Orlando, USA )

Higher local recurrence after skin-sparing than simple mastectomy for DCIS

Prof Nigel Bundred, University of Manchester, Manchester, United Kingdom

Higher local recurrence after skin-sparing than simple mastectomy for DCIS ( Prof Nigel Bundred, University of Manchester, Manchester, United Kingdom )

Peri-operative lapatinib has profound antiproliferative effect in early breast c...

Prof Nigel Bundred - University of Manchester, Manchester, United Kingdom

Peri-operative lapatinib has profound antiproliferative effect in early breast cancer ( Prof Nigel Bundred - University of Manchester, Manchester, United Kingdom )

Guidelines and management of advanced breast cancer in limited resource settings

Prof Nagi S. El Saghir - American University of Beirut, Beirut, Lebanon

Guidelines and management of advanced breast cancer in limited resource settings ( Prof Nagi S. El Saghir - American University of Beirut, Beirut, Lebanon )

New developments and technologies in hereditary cancer

Dr Johnathan Lancaster - Chief Medical Officer of Myriad Genetics, Salt Lake Cit...

New developments and technologies in hereditary cancer ( Dr Johnathan Lancaster - Chief Medical Officer of Myriad Genetics, Salt Lake City, USA )

Results of the CREATE-X trial

Dr Masakazu Toi - Kyoto University, Kyoto, Japan

Results of the CREATE-X trial ( Dr Masakazu Toi - Kyoto University, Kyoto, Japan )

Hormonal treatments produce similar quality of life outcomes in DCIS

Prof Patricia Ganz - UCLA, Los Angeles, USA

Hormonal treatments produce similar quality of life outcomes in DCIS ( Prof Patricia Ganz - UCLA, Los Angeles, USA )

No significant difference in recurrence rates among women with DCIS taking anast...

Prof Jack Cuzick - Wolfson Institute of Prevention Medicine, London, United King...

No significant difference in recurrence rates among women with DCIS taking anastrozole or tamoxifen ( Prof Jack Cuzick - Wolfson Institute of Prevention Medicine, London, United Kingdom )

Treating women with endocrine-resistant HR /HER2 advanced breast cancer

Dr Mario Campone - René Gauducheau Centre de Recherche en Cancérologie, Nantes...

Treating women with endocrine-resistant HR /HER2 advanced breast cancer ( Dr Mario Campone - René Gauducheau Centre de Recherche en Cancérologie, Nantes, France. )

No significant difference in recurrence rates among women with DCIS taking anast...

Prof Jack Cuzick - Wolfson Institute of Prevention Medicine, London, United King...

No significant difference in recurrence rates among women with DCIS taking anastrozole or tamoxifen ( Prof Jack Cuzick - Wolfson Institute of Prevention Medicine, London, United Kingdom )

Patients with DCIS receiving anastrozole reported symptoms different from those ...

Prof Patricia Ganz - UCLA, Los Angeles, USA

Patients with DCIS receiving anastrozole reported symptoms different from those receiving tamoxifen both groups reported similar quality of life ( Prof Patricia Ganz - UCLA, Los Angeles, USA )

Estrogen receptor mutations detected in plasma associated with worse overall sur...

Dr Sarat Chandarlapaty - Memorial Sloan Kettering Cancer Center, New York, USA

Estrogen receptor mutations detected in plasma associated with worse overall survival in metastatic breast cancer ( Dr Sarat Chandarlapaty - Memorial Sloan Kettering Cancer Center, New York, USA )

Improved survival outcomes in women with HER2-negative breast cancer after neoad...

Dr Masakazu Toi - Kyoto university, Kyoto, Japan

Improved survival outcomes in women with HER2-negative breast cancer after neoadjuvant chemotherapy ( Dr Masakazu Toi - Kyoto university, Kyoto, Japan )

Breast-conserving therapy yields better 10-year outcomes than mastectomy for ear...

Dr Sabine Siesling - Netherlands Comprehensive Cancer Organisation, Utrecht, Net...

Breast-conserving therapy yields better 10-year outcomes than mastectomy for early-stage patients ( Dr Sabine Siesling - Netherlands Comprehensive Cancer Organisation, Utrecht, Netherlands )

Adding carboplatin to presurgery chemotherapy improved disease-free survival for...

Prof Gunter von Minckwitz - German Breast Group, Neu-Isenburg, Germany

Adding carboplatin to presurgery chemotherapy improved disease-free survival for patients with triple-negative breast cancer ( Prof Gunter von Minckwitz - German Breast Group, Neu-Isenburg, Germany )

Mastectomy plus reconstruction has higher complication rates and costs than lump...

Prof Benjamin D. Smith - The University of Texas MD Anderson Cancer Center, Hous...

Mastectomy plus reconstruction has higher complication rates and costs than lumpectomy plus radiation ( Prof Benjamin D. Smith - The University of Texas MD Anderson Cancer Center, Houston, USA )

Analysis of blood samples finds ESR1 gene mutations are prevalent and associated...

Dr Sarat Chanderlapaty - Memorial Sloan Kettering Cancer Center, New York, USA

Analysis of blood samples finds ESR1 gene mutations are prevalent and associated with worse overall survival ( Dr Sarat Chanderlapaty - Memorial Sloan Kettering Cancer Center, New York, USA )

Breast-conserving therapy yielded better outcomes than mastectomy for early-stag...

Dr Sabine Siesling - Netherlands Comprehensive Cancer Organisation, Utrecht, Net...

Breast-conserving therapy yielded better outcomes than mastectomy for early-stage patients ( Dr Sabine Siesling - Netherlands Comprehensive Cancer Organisation, Utrecht, Netherlands )

Mastectomy plus reconstruction has higher complication rates and costs than lump...

Prof Benjamin D. Smith - The University of Texas MD Anderson Cancer Center, Hous...

Mastectomy plus reconstruction has higher complication rates and costs than lumpectomy plus radiation ( Prof Benjamin D. Smith - The University of Texas MD Anderson Cancer Center, Houston, USA )

Resistance of ER-positive breast cancer to tamoxifen therapy may be driven by AP...

Dr Reuben Harris - Howard Hughes Medical Institute, Minneapolis, USA

Resistance of ER-positive breast cancer to tamoxifen therapy may be driven by APOBEC3B ( Dr Reuben Harris - Howard Hughes Medical Institute, Minneapolis, USA )

Denosumab improves disease-free survival for postmenopausal patients with HR-pos...

Prof Michael Gnant - Medical University of Vienna, Vienna, Austria

Denosumab improves disease-free survival for postmenopausal patients with HR-positive breast cancer ( Prof Michael Gnant - Medical University of Vienna, Vienna, Austria )

Test to identity which breast cancer patients will respond to platinum-based che...

Dr Johnathan Lancaster - Chief Medical Officer of Myriad Genetics, Salt Lake Cit...

Test to identity which breast cancer patients will respond to platinum-based chemotherapy ( Dr Johnathan Lancaster - Chief Medical Officer of Myriad Genetics, Salt Lake City, USA )

Overexpression of the enzyme APOBEC3B is linked to somatic mutagenesis in breast...

Dr Reuben Harris - Howard Hughes Medical Institute, Chevy Chase, USA

Overexpression of the enzyme APOBEC3B is linked to somatic mutagenesis in breast and other cancers ( Dr Reuben Harris - Howard Hughes Medical Institute, Chevy Chase, USA )

Women with luminal A breast cancer subtype do not seem to benefit from adjuvant ...

Dr Torsten Nielsen - University of British Columbia, Vancouver, Canada

Women with luminal A breast cancer subtype do not seem to benefit from adjuvant chemotherapy ( Dr Torsten Nielsen - University of British Columbia, Vancouver, Canada )

Denosumab improves disease-free survival for postmenopausal HR-positive breast c...

Prof Michael Gnant - Medical University of Vienna, Vienna, Austria

Denosumab improves disease-free survival for postmenopausal HR-positive breast cancer ( Prof Michael Gnant - Medical University of Vienna, Vienna, Austria )

Women with luminal A subtype of breast cancer did not benefit from adjuvant chem...

Dr Torsten Nielsen - University of British Columbia, Vancouver, Canada

Women with luminal A subtype of breast cancer did not benefit from adjuvant chemotherapy ( Dr Torsten Nielsen - University of British Columbia, Vancouver, Canada )

Pathologic complete response to presurgery chemo improves survival for triple-ne...

Dr William Sikov - Women & Infants Hospital of Rhode Island, Providence, USA

Pathologic complete response to presurgery chemo improves survival for triple-negative breast cancer ( Dr William Sikov - Women & Infants Hospital of Rhode Island, Providence, USA )

More from ecancer